Treatment Effect of Cross-frequency Transcranial Alternating Current Stimulation on the MUD

Launched by SHANGHAI MENTAL HEALTH CENTER · Nov 17, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment called cross-frequency transcranial alternating current stimulation (tACS) to see if it can help people with methamphetamine (MA) use disorders. The study aims to find out if multiple sessions of this non-invasive brain stimulation can improve the symptoms and overall well-being of individuals who have been using methamphetamine for at least a year, with their last use being no less than three months ago.

To participate in the trial, individuals must be between the ages of 18 and 65, have normal vision and hearing, and meet the criteria for MA use disorders as defined by mental health guidelines. However, those with certain health issues that affect brain function, a history of serious head injuries, or those who have used other substances (except nicotine) in the past five years will not be eligible. Participants can expect to receive a series of treatment sessions and will be monitored for any changes in their condition. This study is currently recruiting, and it represents a potential new approach to treating methamphetamine dependence.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. In accordance with the Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) for methamphetamine (MA) use disorders
• • 2. Normal vision and hearing
• • 3. Dextromanual
• • 4. Use MA not less than 1 year, and the last of MA use no less than 3 months
• Exclusion Criteria:
• • 1. Have a disease that affects cognitive function such as a history of head injury, cerebrovascular disease, epilepsy, etc
• • 2. Have cognitive-promoting drugs in the last 6 months
• • 3. Other substance abuse or dependence in recent five years (except nicotine)
• • 4. Meet the DSM-5 criteria for other mental disorders
• • 5. Physical disease